IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Provided By GlobeNewswire
Last update: Aug 7, 2025
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today reported financial results and business highlights for the second quarter ended June 30, 2025.
Read more at globenewswire.com
